TRENTON, N.J. (AP) — A panel of Food and Drug Administration advisers voted against approving a new opioid painkiller with a unique feature for deterring abuse: It releases a deep-blue dye if someone tries to get high by crushing, chewing or snorting pills.
Panelists voted overwhelmingly against approving Intellipharmaceutics International’s generic version of extended-release Oxycontin, a key drug in the U.S. opioid addiction epidemic. The FDA usually follows its advisers’ advice.
Doctors and scientists raised many concerns about the dye’s safety for intended patients, and its effectiveness in deterring opioid abusers. Most said the company hadn’t done enough studies of the drug.
Some suggested blue stains around the mouth or nose from trying to abuse the drug could become popular among addicts. Others said the dye’s “Scarlet Letter” shaming approach was insensitive.
Louisiana Lifts Limit on Number of Medical Marijuana Patients Doctors May Treat
Recent Study Finds That Approximately 2 Million US Teens Vape
Study Finds Lesbian, Gay, Bisexual Youth More Likely to Use Multiple Substances
First Ever Trial to Study the Effects of Microdosing LSD Began This Month
News7 days ago
Canadian Dispensary Clerk Fights off Three Burglars With a Giant Bong
Guides7 days ago
The Anatomy of a Marijuana Plant
Guides5 days ago
What To Do With Leftover Marijuana Stems
Entertainment4 days ago
Inside the Ignite Launch with Dan Bilzerian
News5 days ago
U.S. Congressional Committee Approves Cannabis Bill, But Not Without Drama
Celebrities5 days ago
Neil deGrasse Tyson on Elon Musk: ‘Let the Man Get High’
News7 days ago
Nearly 20 Percent of California’s Cannabis Products Failing Lab Tests
News4 days ago
Willie Nelson to Headline Rally for Pro-Cannabis Candidate Beto O’Rourke